Page last updated: 2024-09-03

desloratadine and Cutaneous T-Cell Lymphoma

desloratadine has been researched along with Cutaneous T-Cell Lymphoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Döbbeling, U; Graf, N; Johansen, P; Kündig, TM; Waeckerle-Men, Y; Zabel, F	1

Other Studies

1 other study(ies) available for desloratadine and Cutaneous T-Cell Lymphoma

Article	Year
The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines. Experimental dermatology, 2013, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Clemastine; Cytoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histamine Antagonists; Humans; Loratadine; Lymphoma, T-Cell, Cutaneous; Proto-Oncogene Proteins c-myc; STAT3 Transcription Factor	2013

Article

Year

The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines.

Experimental dermatology, 2013, Volume: 22, Issue:2

Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Clemastine; Cytoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histamine Antagonists; Humans; Loratadine; Lymphoma, T-Cell, Cutaneous; Proto-Oncogene Proteins c-myc; STAT3 Transcription Factor

2013